<?xml version='1.0' encoding='utf-8'?>
<document id="29574985"><sentence text="A robust LC-MS/MS method for the simultaneous determination of docetaxel and voriconazole in rat plasma and its application to pharmacokinetic studies."><entity charOffset="63-72" id="DDI-PubMed.29574985.s1.e0" text="docetaxel" /><entity charOffset="77-89" id="DDI-PubMed.29574985.s1.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.29574985.s1.e0" e2="DDI-PubMed.29574985.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29574985.s1.e0" e2="DDI-PubMed.29574985.s1.e1" /></sentence><sentence text="Opportunistic fungal infections are common in immunocompromised cancer patients, especially patients undergoing chemotherapy" /><sentence text=" Because antitumor agents are possible to combine with antifungal agents in clinical, it is necessary to study drug-drug interaction between antitumor agents and antifungal agents" /><sentence text=" The aim of the study was to explore a method for the simultaneous determination of voriconazole and docetaxel in plasma and investigate pharmacokinetic interaction of voriconazole and docetaxel in rats"><entity charOffset="84-96" id="DDI-PubMed.29574985.s4.e0" text="voriconazole" /><entity charOffset="101-110" id="DDI-PubMed.29574985.s4.e1" text="docetaxel" /><entity charOffset="168-180" id="DDI-PubMed.29574985.s4.e2" text="voriconazole" /><entity charOffset="185-194" id="DDI-PubMed.29574985.s4.e3" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.29574985.s4.e0" e2="DDI-PubMed.29574985.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29574985.s4.e0" e2="DDI-PubMed.29574985.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29574985.s4.e0" e2="DDI-PubMed.29574985.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29574985.s4.e0" e2="DDI-PubMed.29574985.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29574985.s4.e1" e2="DDI-PubMed.29574985.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29574985.s4.e1" e2="DDI-PubMed.29574985.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29574985.s4.e1" e2="DDI-PubMed.29574985.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29574985.s4.e2" e2="DDI-PubMed.29574985.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29574985.s4.e2" e2="DDI-PubMed.29574985.s4.e3" /></sentence><sentence text=" A precise and reliable method using liquid chromatography tandem mass spectrometry (LC-MS/MS) was established for the simultaneous measure of docetaxel and voriconazole in rat plasma after liquid-liquid extraction with ethyl acetate"><entity charOffset="143-152" id="DDI-PubMed.29574985.s5.e0" text="docetaxel" /><entity charOffset="157-169" id="DDI-PubMed.29574985.s5.e1" text="voriconazole" /><entity charOffset="220-233" id="DDI-PubMed.29574985.s5.e2" text="ethyl acetate" /><pair ddi="false" e1="DDI-PubMed.29574985.s5.e0" e2="DDI-PubMed.29574985.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29574985.s5.e0" e2="DDI-PubMed.29574985.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29574985.s5.e0" e2="DDI-PubMed.29574985.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29574985.s5.e1" e2="DDI-PubMed.29574985.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29574985.s5.e1" e2="DDI-PubMed.29574985.s5.e2" /></sentence><sentence text=" The method was fully validated and successfully applied to a pharmacokinetic interaction study of docetaxel and voriconazole in rats after single or combined administration"><entity charOffset="99-108" id="DDI-PubMed.29574985.s6.e0" text="docetaxel" /><entity charOffset="113-125" id="DDI-PubMed.29574985.s6.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.29574985.s6.e0" e2="DDI-PubMed.29574985.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29574985.s6.e0" e2="DDI-PubMed.29574985.s6.e1" /></sentence><sentence text=" We found that the AUC of each drug after coadministration increased compared with that after the single administration, which might be caused by interaction at the absorption stage or the competitive inhibition on the metabolic enzymes" /><sentence text=" This established method can be utilized to study the detailed mechanism of the drug-drug interaction and guide rational drug use in the clinic" /><sentence text="" /></document>